BR112022014397A2 - Compostos co-agonistas de gip/glp1 - Google Patents
Compostos co-agonistas de gip/glp1Info
- Publication number
- BR112022014397A2 BR112022014397A2 BR112022014397A BR112022014397A BR112022014397A2 BR 112022014397 A2 BR112022014397 A2 BR 112022014397A2 BR 112022014397 A BR112022014397 A BR 112022014397A BR 112022014397 A BR112022014397 A BR 112022014397A BR 112022014397 A2 BR112022014397 A2 BR 112022014397A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- gip
- glp1
- relates
- present
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 7
- 108091016366 Histone-lysine N-methyltransferase EHMT1 Proteins 0.000 title abstract 2
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 abstract 1
- 102100039994 Gastric inhibitory polypeptide Human genes 0.000 abstract 1
- 101000886868 Homo sapiens Gastric inhibitory polypeptide Proteins 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 102100040918 Pro-glucagon Human genes 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2235—Secretins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/645—Secretins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062964932P | 2020-01-23 | 2020-01-23 | |
| PCT/US2021/014302 WO2021150673A1 (en) | 2020-01-23 | 2021-01-21 | Gip/glp1 co-agonist compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022014397A2 true BR112022014397A2 (pt) | 2022-10-11 |
Family
ID=74592824
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022014397A BR112022014397A2 (pt) | 2020-01-23 | 2021-01-21 | Compostos co-agonistas de gip/glp1 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230265151A1 (https=) |
| EP (1) | EP4093757A1 (https=) |
| JP (1) | JP2023511441A (https=) |
| KR (1) | KR20220131292A (https=) |
| CN (1) | CN115298207A (https=) |
| AR (1) | AR121093A1 (https=) |
| AU (1) | AU2021211451B2 (https=) |
| BR (1) | BR112022014397A2 (https=) |
| CA (1) | CA3165430A1 (https=) |
| IL (1) | IL294955A (https=) |
| MX (1) | MX2022009149A (https=) |
| TW (1) | TWI770781B (https=) |
| WO (1) | WO2021150673A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI912614B (zh) * | 2017-12-21 | 2026-01-21 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
| WO2022159395A1 (en) | 2021-01-20 | 2022-07-28 | Viking Therapeutics, Inc. | Compositions and methods for the treatment of metabolic and liver disorders |
| JP2024508745A (ja) * | 2021-02-17 | 2024-02-28 | イーライ リリー アンド カンパニー | Ｇｉｐ／ｇｌｐ１デュアルアゴニスト治療方法 |
| IL310377A (en) | 2021-08-30 | 2024-03-01 | Mindrank Ai Ltd | Novel aryl ether substituted heterocyclic compound as glp1r agonist |
| MX2024003236A (es) | 2021-09-15 | 2024-06-19 | Viking Therapeutics Inc | Composiciones y metodos para el tratamiento de trastornos metabolicos y hepaticos. |
| CN117586373A (zh) * | 2022-08-10 | 2024-02-23 | 成都奥达生物科技有限公司 | 一种长效双激动剂化合物 |
| CN116023444B (zh) * | 2022-08-12 | 2023-08-01 | 重庆宸安生物制药有限公司 | 一种gip和glp-1双受体激动剂多肽化合物及其应用 |
| WO2024165571A2 (en) | 2023-02-06 | 2024-08-15 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| WO2025125576A2 (en) | 2023-12-15 | 2025-06-19 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| WO2025133348A1 (en) | 2023-12-22 | 2025-06-26 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| EP4686757A1 (en) | 2024-07-31 | 2026-02-04 | e-therapeutics PLC | Inhibitors of expression and/or function |
| WO2025196502A1 (en) | 2024-03-20 | 2025-09-25 | North Carolina Agricultural & Technical State University | Choline kinase inhibitors as a therapeutic treatment for obesity |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR080592A1 (es) * | 2010-03-26 | 2012-04-18 | Lilly Co Eli | Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso |
| WO2012167744A1 (en) * | 2011-06-10 | 2012-12-13 | Beijing Hanmi Pharmaceutical Co., Ltd. | Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof |
| JP6228187B2 (ja) * | 2012-05-03 | 2017-11-08 | ジーランド ファーマ アクティーゼルスカブ | Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法 |
| HK1211232A1 (en) * | 2012-12-21 | 2016-05-20 | Sanofi | Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists |
| MX2016005556A (es) * | 2013-11-06 | 2016-07-15 | Zealand Pharma As | Compuestos agonistas duales de gip-glp-1 y procedimientos. |
| JO3575B1 (ar) | 2015-01-09 | 2020-07-05 | Lilly Co Eli | مركبات مساعد مشترك من gip وglp-1 |
| TWI783244B (zh) * | 2015-06-22 | 2022-11-11 | 美商美國禮來大藥廠 | 升糖素及glp-1共激動劑化合物 |
| TWI767095B (zh) * | 2017-12-21 | 2022-06-11 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
| CN112469731B (zh) * | 2018-07-23 | 2024-11-29 | 伊莱利利公司 | Gip/glp1共激动剂化合物 |
-
2021
- 2021-01-21 WO PCT/US2021/014302 patent/WO2021150673A1/en not_active Ceased
- 2021-01-21 AR ARP210100135A patent/AR121093A1/es unknown
- 2021-01-21 EP EP21705072.3A patent/EP4093757A1/en active Pending
- 2021-01-21 JP JP2022544753A patent/JP2023511441A/ja active Pending
- 2021-01-21 US US17/794,128 patent/US20230265151A1/en active Pending
- 2021-01-21 AU AU2021211451A patent/AU2021211451B2/en active Active
- 2021-01-21 IL IL294955A patent/IL294955A/en unknown
- 2021-01-21 TW TW110102332A patent/TWI770781B/zh active
- 2021-01-21 BR BR112022014397A patent/BR112022014397A2/pt unknown
- 2021-01-21 CA CA3165430A patent/CA3165430A1/en active Pending
- 2021-01-21 MX MX2022009149A patent/MX2022009149A/es unknown
- 2021-01-21 KR KR1020227028667A patent/KR20220131292A/ko not_active Withdrawn
- 2021-01-21 CN CN202180023819.8A patent/CN115298207A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023511441A (ja) | 2023-03-17 |
| IL294955A (en) | 2022-09-01 |
| US20230265151A1 (en) | 2023-08-24 |
| TW202140528A (zh) | 2021-11-01 |
| EP4093757A1 (en) | 2022-11-30 |
| AU2021211451B2 (en) | 2023-11-02 |
| WO2021150673A1 (en) | 2021-07-29 |
| KR20220131292A (ko) | 2022-09-27 |
| AR121093A1 (es) | 2022-04-20 |
| TWI770781B (zh) | 2022-07-11 |
| MX2022009149A (es) | 2022-12-15 |
| AU2021211451A1 (en) | 2022-08-18 |
| CA3165430A1 (en) | 2021-07-29 |
| CN115298207A (zh) | 2022-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022014397A2 (pt) | Compostos co-agonistas de gip/glp1 | |
| MX2021000793A (es) | Compuestos coagonistas de gip/glp1. | |
| Williams et al. | Drug therapy in obesity: a review of current and emerging treatments | |
| Rehfeld | The origin and understanding of the incretin concept | |
| Mehta et al. | Liraglutide for weight management: a critical review of the evidence | |
| Van Gaal et al. | Weight management in type 2 diabetes: current and emerging approaches to treatment | |
| BR112022023834A2 (pt) | Composto duplo-agonista para os receptores de glp-1 e gip e aplicação do mesmo | |
| BR0213377A (pt) | mìmico de peptìdeo semelhante ao glucagon 1 humano e seu uso no tratamento de diabetes e condições relacionadas | |
| DE60327771D1 (de) | Glp-1 und behandlungsmethode für diabetes | |
| EA201370099A1 (ru) | Терапия на основе лигандов хемосенсорных рецепторов | |
| JP2014504588A5 (https=) | ||
| El-Solh et al. | Current perspectives on the use of GLP-1 receptor agonists in obesity-related obstructive sleep apnea: a narrative review | |
| Agius et al. | GLP-1 analogues in clinical management of obesity | |
| Chen et al. | Exenatide twice daily plus glargine versus aspart 70/30 twice daily in patients with type 2 diabetes with inadequate glycemic control on premixed human insulin and metformin | |
| Fowler | Diabetes treatment, Part 3: insulin and incretins. | |
| McKone et al. | Evaluation of insulin dosage after the addition of Tirzepatide compared with Semaglutide or Dulaglutide in patients with type 2 diabetes | |
| Lozano et al. | Real-world evaluation of the efficacy and safety of switching from weekly dulaglutide to weekly semaglutide: The SEMA-SWITCH study | |
| Nikkar et al. | Review of the mechanism and function of glucagon-like peptide 1 (GLP-1) and GLP-1 receptor agonists in the improvement of type 2 diabetes | |
| Siddhanta | New Kid on the Block: Semaglutide | |
| EA202092891A1 (ru) | Соединения-коагонисты gip/glp1 | |
| TH2101000319A (th) | สารประกอบอะโกนิสท์ร่วม gip/glp1 | |
| Chen et al. | Review of Glucagon-Like Peptide 1 and Glucose-Dependent Insulinotropic Polypeptide Agonists for Treatment of Adult Obese Patients with Obstructive Sleep Apnea | |
| Chen | New management choices in type 2 diabetes | |
| Malhotra et al. | Exenatide-A Turning Point InPharmacotherapy of NIDDM | |
| Koteshkova et al. | EFFICIENCY OF MULTICOMPONENT THERAPY IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (CLINICAL CASE) |